Open Nav

RxMP Therapeutic, Inc.

  • Rifat Pamukcu, RxMP Therapeutics, Inc.

Raising Series A financing

  • Date:Wednesday, October 17
  • Time:9:30 AM - 9:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:RxMP Therapeutics, Inc. (RxMP) is an emerging specialty therapeutics company focused on developing proprietary drugs for the management of excessive bleeding. RxMP aims to develop and commercialize RMP-HPEs, (red cell-derived microparticles produced by high-pressure extrusion), as a first-in-class hemostatic agent for the treatment or prevention of excessive bleeding. Our product’s initial target market is in those patients at risk of excessive bleeding during spinal surgery, a worldwide market opportunity of over $900M, with expansion potential of $4.6B in additional clinical indications of excessive bleeding. Our platform technology capitalizes on the finding that RMP-HPEs, when administered systemically in the setting of acute bleeding, will stop the bleeding without the risk of undesirable clotting elsewhere in the body.
  • Company Website:www.rxmpt.com
  • Company HQ City:Miami
  • Company HQ Country:United States
  • Company HQ State:Florida                        
  • CEO/Top Company Official:Rifat Pamukcu, MD FAIMBE
  • Year Founded:2013
  • Main Therapeutic Focus:Other
  • Lead Product in Development :RMP-402
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Additional Information/Comments:RxMP is looking to raise up to $17M to advance our lead product, RMP-402, through the remainder of preclinical development and through Phase 2 clinical studies. Use of funds is $3M through IND filing and $11M for human studies through Phase 2a proof-of-concept, completing late 2020, and Phase 2b. RMP-402 has demonstrated efficacy in multiple animal models and across species with a high level of safety. Based on the guidance the Company received from a meeting with the FDA, the Company is targeting the start of clinical trials later in 2019 in our initial indication. We believe our lead product RMP-402 represents a compelling opportunity as the first new systemically administered hemostatic agent in over a decade.
  • Previous and Current Investors:Wallace H. Coulter Foundation, Florida Institute Venture Fund
  • Size of Last Investment Round:$1.7 M
  • Total Amount Raised to Date, In All Rounds:$2.8 M
Speakers
Rifat Pamukcu
RxMP Therapeutics, Inc.
Back